TWI794847B - Composition for reducing metabolic syndrome and application thereof - Google Patents

Abstract

The present invention relates to a composition for reducing metabolic syndrome. The composition includes anEmblica extract and a second compound, which is a turmeric extract, and/or aGarcinia cambogia extract, and/or anIrvingia gabonensis extract, and/or aPhaseolus vulgaris extract, and/or aCamellia japonica seed extract, and/or a coffee extract. The present invention also relates to application of the composition for reducing metabolic syndrome.

Description

Composition and use thereof for reducing metabolic syndrome

The present invention relates to a composition for reducing metabolic syndrome and its application, especially a composition containing emblica extract with synergistic effect and its application.

Metabolic syndrome is a general term for a group of risk factors that easily lead to cardiovascular disease, not a disease. According to the judgment criteria revised by the National Health Bureau of the Department of Health, Executive Yuan in 2006, the following five components, if three or more of the following factors are met, can be judged as metabolic syndrome: (1) Abdominal obesity: male waist circumference ≥ 90 cm, Female waist circumference ≥ 80 cm; (2) high blood pressure: systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg; (3) fasting blood sugar level , FG) high: FG ≥ 100 mg/dL; (4) triglyceride (triglyceride, TG) high: TG ≥ 150 mg/dL; (5) high-density lipoprotein cholesterol (High-density lipoprotein cholesterol, HDL-C) is too low: men < 40 mg/dL, women < 50 mg/dL.

Although metabolic syndrome is not a specific disease, metabolic syndrome is the precursor of diabetes and cardiovascular disease. People with metabolic syndrome are 6, 4, 3, and 2 times more likely to develop "diabetes," "high blood pressure," "hyperlipidemia," "heart disease, and stroke" in the future, respectively, than normal healthy people. According to the National Health Administration of the Ministry of Health and Welfare previously announced the top 10 causes of death in 2013, it was found that heart disease, cerebrovascular disease, diabetes, hypertension, kidney disease and other causes of death related to metabolic syndrome accounted for 31.1% of all deaths. Beyond cancer 29%, and breast cancer, colorectal cancer have also been confirmed to be related to obesity.

According to a survey by the Ministry of Health and Welfare, the prevalence rate of metabolic syndrome in Taiwan over the age of 20 is 19.7%, and about 1 in every 5 people has metabolic syndrome. The treatment of metabolic syndrome is mainly based on changing the lifestyle. The current mainstream of treatment is regular exercise combined with dietary changes. However, the effects of exercise and diet are relatively slow, and patients tend to give up treatment halfway. Therefore, if there are other ways to assist or promote the reduction of symptoms and occurrence of metabolic syndrome, it will be a better solution.

In one aspect, the present invention provides a composition for reducing metabolic syndrome, comprising: an emblica extract, whose weight percentage is 10%~75%, and a second component, which is a turmeric extract, and /or a garcinia cambogia extract, and/or an African mango extract, and/or a white kidney bean extract, and/or a camellia seed extract, and/or a coffee extract, and the second composition The percentage by weight is 25%~90%.

Another aspect of the present invention provides a use of the above composition in the preparation of a pharmaceutical composition for reducing metabolic syndrome.

The present invention is illustrated by the following examples, but the present invention is not limited by the following examples.

It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory, and are not intended to limit the scope of the patent application for the present invention. Certain details of one or more embodiments of the invention are set forth in the description below. Other characteristics or advantages of the present invention will be apparent from the following non-exhaustive list of representative embodiments, also from the appended claims.

The present invention firstly provides a composition for reducing metabolic syndrome, comprising: a emblica extract, whose weight percentage is 10%~75%, and a second component, which is a turmeric extract, and/or A garcinia cambogia extract, and/or an African mango extract, and/or a white kidney bean extract, and/or a camellia seed extract, and/or a coffee extract, and the second component The weight percentage is 25%~90%. The extract of Amla emblica in the composition provided by the present invention can enhance the original effect of the second component on reducing blood fat, blood sugar, weight loss, etc. Compared with those, the post-metabolism index of the subjects who used the composition of the present invention significantly decreased, which had an unexpected synergistic effect.

In some embodiments, the second component is the turmeric extract, and its weight percentage is 25%-75%, and the weight percentage of the emblica extract is 25%-75%. In some specific embodiments, the weight percent of the turmeric extract is 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, The weight percent of the Amla emblica extract is 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%.

In some embodiments, the second component is the garcinia cambogia extract, the weight percentage of which is 40%-85%, and the weight percentage of the emblica extract is 15%-60%. In some specific embodiments, the weight percent of the garcinia cambogia extract is 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85%, and The weight percent of the emblica extract is 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15%.

In some embodiments, the second component is the African mango extract, which is 55%-90% by weight, and the emblica extract, which is 10%-45% by weight. In some specific embodiments, the weight percentage of the African mango extract is 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%, and the weight percentage of the emblica extract The percentages are 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%.

In some embodiments, the second component is the white kidney bean extract, the weight percentage of which is 40%-85%, and the weight percentage of the emblica extract is 15%-60%. In some specific embodiments, the weight percent of the white kidney bean extract is 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85%, and The weight percent of the emblica extract is 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15%.

In some embodiments, the second component is the camellia seed extract, the weight percentage of which is 55%-90%, and the weight percentage of the emblica seed extract is 10%-45%. In some specific embodiments, the weight percentage of the camellia seed extract is 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%, and the weight percentage of the emblica seed extract The percentages are 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%.

In some embodiments, the second component is the coffee extract, the weight percentage of which is 50%-90%, and the weight percentage of the emblica extract is 10%-50%. In some specific embodiments, the weight percentage of the coffee extract is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%, and the emblica extract The weight percentage is 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%.

As used herein, the term "emblicanin extract" refers to an extract containing emblicanin-A (Emblicanin-A) and emblicanin-B (Emblicanin-B). In some embodiments, the emblica extract contains 20% to 30% by weight of emblicanin-A (Emblicanin-A), 20% to 30% by weight of emblicanin-B (Emblicanin-B) , 5% to 10% by weight of pomegranate (Punigluconin), 10% to 20% by weight of aristolochine (Pedunculagin), 5% to 15% by weight of rutin (Rutin), and 10%~30% Gallo-ellagitannins. In a specific embodiment, the emblica extract contains 27% by weight of emblicanin-A (Emblicanin-A), 23% by weight of emblicanin-B (Emblicanin-B), 8% by weight of Punigluconin, 14% by weight of aristolochiin (Pedunculagin), 10% by weight of rutin (Rutin), and 18% by weight of ellagitannins (Gallo-ellagitannins).

As used herein, the term "turmeric extract" refers to an extract containing curcumin. In some embodiments, the turmeric extract contains 80%-100% curcumin by weight. In a specific embodiment, the turmeric extract contains 95% curcumin by weight.

As used herein, the term "garcinia cambogia extract" refers to an extract containing hydroxycitric acid (Hydroxy Citric acid, HCA). In some embodiments, the garcinia cambogia extract contains 60%-62% by weight of hydroxycitric acid. In a specific embodiment, the garcinia cambogia extract contains 60% by weight of hydroxycitric acid.

As used herein, the term "African mango extract" refers to an extract containing albumin and ellagic acid. In some embodiments, the African mango extract contains more than 10% by weight of albumin and 0.96%-1.44% by weight of ellagic acid.

As used herein, the term "white kidney bean extract" refers to an extract containing an α-amylase inhibitor. In certain embodiments, the white kidney bean extract contains at least 3000 α-amylase inhibitors per gram using potato starch as the test substrate and pancreatin as the enzyme source in a pH 6.8 environment. Alpha amylase inhibitor units (alpha amylase inhibiting units, AAIU).

As used herein, the term "camellia seed extract" refers to an extract containing camellia saponins. In some embodiments, the camellia seed extract contains 20%-30% by weight of camellia saponins. In a specific embodiment, the camellia seed extract contains 25% by weight of camellia saponins.

As used herein, the term "coffee extract" refers to an extract containing chlorogenic acid and caffeine. In some embodiments, the coffee extract contains more than 15% by weight of chlorogenic acid and more than 70 mg/g of caffeine. In a specific embodiment, the coffee extract contains 15% by weight of chlorogenic acid and 75 mg/g of caffeine.

As used herein, the term "metabolic syndrome" refers to a patient with metabolic syndrome who meets at least three of the following five components according to the criteria revised by the National Health Bureau of the Ministry of Health, Executive Yuan in 2006: (1) Abdominal obesity: waist circumference ≥ 90 cm for men and ≥ 80 cm for women; (2) High blood pressure: systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg; (3) High fasting blood glucose (FG): FG ≥ 100 mg/dL; (4) High triglyceride (TG): TG ≥ 150 mg/dL; (5) Low high-density lipoprotein cholesterol (HDL-C): men < 40 mg/dL, women < 50 mg/dL.

As used herein, the term "reducing metabolic syndrome" means capable of treating metabolic syndrome, reducing or eliminating symptoms of metabolic syndrome, and/or substantially preventing or preventing the occurrence of metabolic syndrome. In some embodiments, reducing metabolic syndrome refers to a subject with metabolic syndrome, after a period of time after administering the composition of the present invention, compared with the subject before administering the composition of the present invention, the subject has Body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and at least 5, preferably 6, and more preferably 7 of the physiological indicators of the test subject , the best 8 physiological indicators decreased significantly, and the subject's high-density lipoprotein cholesterol (HDL-C) index increased significantly.

As used herein, the term "additive effect" refers to a subject with metabolic syndrome after administering the composition of the present invention for a period of time, and another subject with metabolic syndrome after administering the composition of the present invention The body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and At least 5 of the physiological indicators such as BMI, preferably 6, more preferably 7, and the best 8 physiological indicators are significantly reduced, and the high-density lipoprotein cholesterol (HDL-C) of the experimenter who uses the composition of the present invention The index rose significantly. In some embodiments, the second component is a turmeric extract, and/or a garcinia cambogia extract, and/or an African mango extract, and/or a white kidney bean extract, and/or or a camellia seed extract, and/or a coffee extract.

In some preferred embodiments, the composition provided by the present invention further comprises a pharmaceutically acceptable carrier.

As used herein, the term "pharmaceutically acceptable carrier" refers to any substance or combination thereof that can be physically or chemically mixed, dissolved, suspended, or otherwise combined with the composition of the present invention to produce the pharmaceutical composition of the present invention. combination. According to the present invention, the pharmaceutically acceptable carrier includes, but is not limited to, one or more agents selected from the group consisting of: solvent, emulsifier, suspending agent, decomposer ), binder (binding agent), excipient (excipient), stabilizer (stabilizing agent), chelating agent (chelating agent), diluent (diluent), gelling agent (gelling agent), preservative (preservative), Lubricant, surfactant, adjuvant, and other similar or applicable carriers of the present invention. In some preferred embodiments, the pharmaceutically acceptable carrier is an excipient.

According to the present invention, the excipients include, but are not limited to, disintegrants, binders, fillers, lubricants, suspending agents, cosolvents ( solubilizer) and glidant. The amount of excipient used depends on how much active ingredient and dosage form are used, and an excipient can perform more than one function. In certain preferred embodiments, the excipient is a filler.

In some embodiments, the filler includes, but is not limited to, calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, carboxylate Calcium carboxymethylcellulose, cellulose, dextrin, salt, dextrin, dextrose, fructose, lactitol , lactose, carbonate, magnesium oxide, maltitol, maltodextrin, maltose, sorbitol, starch, sucrose ), sugar and xylitol. In some preferred embodiments, the filler is maltodextrin.

The present invention also provides an application of the above-mentioned composition in preparing a medicinal composition for reducing metabolic syndrome. In certain embodiments, the pharmaceutical composition is orally administered to a human subject in an effective dose.

In certain embodiments, the effective dose is 1000 mg to 5000 mg per day. In certain embodiments, the effective dose is 1000 mg, 1500 mg, 2000 mg, 2500 mg, 3000 mg, 3500 mg, 4000 mg, 4500 mg, or 5000 mg per day.

As used herein, the term "pharmaceutical composition" refers to any preparation in which a composition of the invention can be formulated, stored, preserved, altered, administered, or a combination thereof. As described below, the formulation may include any pharmaceutically acceptable diluents, adjuvants, buffers, excipients, carriers or combinations thereof. In general, the components of the formulation are selected on the basis of the mode and route of administration, and standard pharmaceutical practice.

As used herein, the term "effective dose" means capable or sufficient to maintain or produce a desired physiological result, including, but not limited to, treating, alleviating, eliminating, substantially preventing or preventing, or a combination thereof, a disease, disorder, or its combination. An effective dose may comprise one or more doses administered sequentially or simultaneously. Those skilled in the art of the invention will know to adjust dosages of the present invention to take into account various types of formulations including, but not limited to, sustained release formulations. As used herein, the term "prevention" means a composition that substantially prevents or prevents a disease, disorder, or any aspect of a combination thereof. As used herein, the term "therapeutic" means capable of treating, reducing, halting progression, slowing progression, favorably altering, eliminating, or a combination thereof, any aspect of a disease, disorder, or combination thereof.

As used herein, the term "subject" means any subject to which the present invention is administered. A subject can be, for example, a mammal. A subject can be a human or a veterinary animal, regardless of sex, age, or any combination thereof, and includes a fetus. A subject can optionally be affected by, or be at risk for, a particular disease, condition, or combination thereof.

Formulations suitable for administration according to the invention may include, possibly among other things known to those skilled in the art: aqueous and non-aqueous solutions, antioxidants, bacteriostats, buffers, solutes that affect isotonicity, preservatives, Solubilizers, stabilizers, suspending agents, thickeners, or combinations thereof.

Additionally or in the alternative, formulations suitable for administration according to the invention may include, possibly among other things known to those skilled in the art: gel, PEG such as PEG 400, propylene glycol, saline, sachet; Other suitable liquids known in the art, or combinations thereof.

Additionally or in the alternative, formulations suitable for administration according to the invention may include, possibly among other things known to those skilled in the art: binders, buffers, calcium phosphate, cellulose, colloids, such as colloidal silicon dioxide , coloring agent, diluent, disintegrant, dye, filler, flavoring agent, gelatin, lactose, magnesium stearate, mannitol, microcrystalline gelatin, wetting agent, paraffin, lozenge, polyethylene glycol, preservative agent, sorbitol, starch, such as corn starch, potato starch, or combinations thereof, stearic acid, sucrose, talc, triglycerides, or combinations thereof.

Additionally or in the alternative, formulations suitable for administration according to the invention may include, possibly among other things known to those skilled in the art: alcohols, such as benzyl alcohol or ethanol, benzalkonium chloride, buffers such as phosphate buffered saline Acetate buffer, citrate buffer, or combinations thereof, carboxymethylcellulose or microcrystalline cellulose, cholesterol, dextrose, fruit juices such as grapefruit juice, milk, phospholipids such as lecithin, oils such as vegetable oils, fish oils , or mineral oil, or a combination thereof; other pharmaceutically compatible carriers known in the art; or a combination thereof.

Additionally or alternatively, formulations suitable for administration according to the invention may include, possibly among other things known to those skilled in the art: biodegradable, such as polylactic-polyglycolic acid (PLGA) polymers, Degradation products of other entities can be rapidly cleared from a biological system, or a combination thereof.

The formulations of the invention can be administered in unit dose form, in multiple dose form, or in combinations thereof. They can be packaged in unit dose containers, multi-dose containers, or combinations thereof. The invention may be present in ampoules, caplets, capsules, granules, troches, powders, tablets, vials, emulsions, including but not limited to latex arabic emulsions, suspensions, or combinations thereof.

As used herein, the singular forms "a", "a" and "the" include plural forms unless the context clearly dictates otherwise. Thus, for example, reference to "a sample" includes a plurality of such samples and equivalents known to those of ordinary skill in the art.

The term "about", "approximately" or "approximately" as used herein essentially means that the stated value or range is within 20%, preferably within 10%, and more preferably within 5%. Numerical quantities provided herein are approximations and are intended to be inferred if the terms "about", "approximately" or "approximately" are not used.

All technical and scientific terms described in this specification, unless otherwise defined, have meanings commonly understood by those skilled in the art.

The invention is further illustrated by the following examples, which are provided for purposes of illustration and not limitation. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example human trials

In this embodiment, 60 male and 60 female human subjects aged between 40 and 60 years old, a total of 120 people were used as test subjects. All subjects had metabolic syndrome, that is, all subjects met at least three of the following conditions: (1) Abdominal obesity: waist circumference ≥ 90 cm for men and ≥ 80 cm for women; (2) High blood pressure: systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg; (3) High fasting blood glucose (FG): FG ≥ 100 mg/dL; (4) High triglyceride (TG): TG ≥ 150 mg/dL; (5) Low high-density lipoprotein cholesterol (HDL-C): men < 40 mg/dL, women < 50 mg/dL. The subjects were randomly divided into 12 groups, 5 males and 5 females in each group, 6 control groups and 6 experimental groups respectively.

An 8-week single-blind trial was conducted without changing individual dietary habits. The subjects in each group were treated with the following compositions every day. The treatment method was that the subjects in each group took the composition in capsule form twice a day, two capsules each time (500 mg/capsule), before lunch respectively Take 30 minutes and 30 minutes before dinner. The total doses of the composition taken by each group of subjects per day are respectively: Control group 1: turmeric extract 500 mg + maltodextrin 1500 mg; Test group 1: emblica extract 200 mg + turmeric extract 500 mg + maltodextrin 1300 mg; Control group 2: Garcinia cambogia extract 1500 mg + maltodextrin 500 mg; Test group 2: emblica extract 200 mg + garcinia cambogia extract 1500 mg + maltodextrin 300 mg; Control group 3: African mango extract 300 mg + maltodextrin 1700 mg; Test group 3: emblica extract 200 mg + African mango extract 300 mg + maltodextrin 1500 mg; Control group 4: white kidney bean extract 1500 mg + maltodextrin 500 mg; Test group 4: emblica extract 200 mg + white kidney bean extract 1500 mg + maltodextrin 300 mg; Control group 5: camellia seed extract 300 mg + maltodextrin 1700 mg; Test group 5: emblica extract 200 mg + camellia seed extract 300 mg + maltodextrin 1500 mg; Control group 6: 1700 mg of espresso powder + 300 mg of maltodextrin; Test group 6: emblica extract 200 mg + espresso powder 1700 mg + maltodextrin 100 mg.

Before the start of the test (the 0th day of the test), the following physiological indicators were measured and recorded for each subject, as a basis for comparison before and after the test. The physiological indicators tested include: (1) Weight, waist circumference, body mass index (BMI), blood pressure measurement: once a week, with the same machine and at the same time every week to measure and record; (2) Blood test: Blood was drawn for each subject to detect blood cholesterol, low-density lipoprotein cholesterol (Low-density lipoprotein cholesterol, LDL-C), triglycerides, high-density lipoprotein cholesterol ( HDL-C), and blood sugar, were tested and recorded every four weeks.

Data analysis and statistical methods: compare the physiological index values measured by each group during the test with the corresponding values measured by each group before the start of the test (the 0th day of the test), and record the results at the end of the test (the 8th week) The difference between the value of each physiological index before the start of the test (the 0th day of the test), and the records of each physiological index before the start of the test and at the end of the test of each test group are shown in Table 1-1~Table 1-3. And each control group was used as the standard, compared with the corresponding test group, analyzed and verified by Student's t-test, when the p value was less than 0.05, it was considered that there was a significant difference between the test group and the control group. The statistical results are shown in Table 2~Table 7 respectively.

Table 1-1 Records of various physiological indicators of each test group before the start of the test and at the end of the test Physiological indicators Test group 1 (emblica + turmeric extract) Test group 2 (emblica + garcinia cambogia extract) Before the test at the end of the test Before the test at the end of the test Body fat percentage (%) 47.00 39.86 45.00 41.50 Cholesterol (mg/dl) 225 187.4 223 203.6 LDL-C (mg/dl) 137.5 114.52 137 125.1 Triglycerides (mg/dl) 249 209.66 235 212.62 HDL-C (mg/dl) 30.7 34.42 32.8 36.15 Blood sugar (mg/dl) 145.7 131.11 138 124.61 Waist (cm) 90 86 91.5 86 weight(kg) 78 74.1 80 75 BMI 31.2 30.57 38 34.8

Table 1-2 Records of various physiological indicators of each test group before the start of the test and at the end of the test Physiological indicators Experimental group 3 (emblica + African mango extract) Test group 4 (emblica + white kidney bean extract) Before the test at the end of the test Before the test at the end of the test Body fat percentage (%) 47.00 42.24 47.00 43.58 Cholesterol (mg/dl) 227 188.2 230 213.4 LDL-C (mg/dl) 145.3 120.5 142 131.8 Triglycerides (mg/dl) 251 210.06 257 197.56 HDL-C (mg/dl) 37 43.29 38.5 41.8 Blood sugar (mg/dl) 152 125.54 175 96.25 Waist (cm) 100 82 100.5 95.5 weight(kg) 87.4 79 80.5 75.99 BMI 42.8 37.66 39 36.27

Table 1-3 Records of various physiological indicators of each test group before the start of the test and at the end of the test Physiological indicators Test group 5 (emblica + camellia extract) Test group 6 (emblica extract + espresso) Before the test at the end of the test Before the test at the end of the test Body fat percentage (%) 46.00 43.37 47.00 42.52 Cholesterol (mg/dl) 231 187.8 233 181.6 LDL-C (mg/dl) 137 111.4 148.5 115.7 Triglycerides (mg/dl) 238 223.22 257 229.76 HDL-C (mg/dl) 39 42.28 36.5 40.3 Blood sugar (mg/dl) 136.4 125.35 147.8 131.08 Waist (cm) 97.5 94.5 101.5 97.5 weight(kg) 78 75 84.6 80.9 BMI 34 32.63 39 36.27

It can be seen from Table 2 that the subjects in the test group who took 200 mg of Amla emblica extract, 500 mg of turmeric extract and 1300 mg of excipient maltodextrin daily for 8 weeks had lower body fat, cholesterol, low-density lipoprotein Physiological indicators such as cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and BMI all decreased compared with the corresponding physiological indicators before the start of the test (test day 0), while the other High-density lipoprotein cholesterol (HDL-C) in the blood increased after 8 weeks of testing, and body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, and BMI, etc. The degree of decrease in physiological indicators, as well as the degree of increase in their high-density lipoprotein cholesterol (HDL-C), compared with control group 1 subjects who took only turmeric extract 500 mg with excipient maltodextrin 1500 mg for 8 weeks There are significant differences in comparison. The results show that when the emblica extract and turmeric extract are used in combination, it has an unexpected synergistic effect on the original effects of turmeric extract on lowering blood fat, blood sugar, and weight loss.

Table 2 Changes of various physiological indicators of subjects in control group 1 and test group 1 before the start of the test and at the end of the test Physiological indicators Control group 1 turmeric extract 500 mg Test group 1 Amla extract 200 mg + turmeric extract 500 mg Statistical Analysis reduce body fat 9.7% 15.2% p < 0.05 reduce cholesterol 10.1% 16.7% p < 0.05 Lower LDL-C 8.7% 14.5% p < 0.05 lower triglycerides 10.5% 15.8% p < 0.05 Improve HDL-C 4.7% 12.1% p < 0.05 lower blood sugar 2.7% 10.0% p < 0.05 Lower waist (cm) 1.5 4.0 p > 0.05 Weight loss (kg) 1.5 3.9 p > 0.05 Lower BMI 2.0% 5.0% p < 0.05

It can be seen from Table 3 that the body fat, cholesterol, low density Physiological indicators such as lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and BMI all decreased compared with the corresponding physiological indicators before the start of the test (test day 0), However, the high-density lipoprotein cholesterol (HDL-C) in the blood increased after the 8-week test, and the body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference , body weight, and the degree of decline in physiological indicators such as BMI, as well as the degree of increase in high-density lipoprotein cholesterol (HDL-C), compared with only taking 1500 mg of garcinia cambogia extract and 500 mg of excipient maltodextrin for a total of 8 Compared with the control group 2 subjects, there were significant differences. The results show that when the emblica extract and the garcinia cambogia extract are used in combination, it has an unexpected synergistic effect on the original effects of the garcinia cambogia extract on lowering blood fat, blood sugar, and weight loss.

Table 3 Changes of various physiological indicators of subjects in control group 2 and test group 2 before the start of the test and at the end of the test Physiological indicators Control group 2 Garcinia cambogia extract 1500 mg Test group 2 Amla extract 200 mg + Garcinia cambogia extract 1500 mg Statistical Analysis reduce body fat 2.7% 7.8% p < 0.05 reduce cholesterol 3.5% 8.7% p < 0.05 Lower LDL-C 6.3% 14.3% p < 0.05 lower triglycerides 4.5% 9.5% p < 0.05 Improve HDL-C 4.0% 10.2% p < 0.05 lower blood sugar 2.2% 9.7% p < 0.05 Lower waist (cm) 1.3 5.5 p < 0.05 Weight loss (kg) 2.7 5 p < 0.05 Lower BMI 2.6% 8.4% p < 0.05

It can be seen from Table 4 that the body fat, cholesterol, low-density fat Protein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and BMI and other physiological indicators were all decreased compared with the corresponding physiological indicators before the start of the test (test day 0), while The high-density lipoprotein cholesterol (HDL-C) in the blood increased after the 8-week test, and the body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, Body weight, as well as the degree of decline in physiological indicators such as BMI, and the degree of increase in high-density lipoprotein cholesterol (HDL-C), compared with those who only took 300 mg of African mango extract and 1700 mg of excipient maltodextrin for 8 weeks Compared with the 3 subjects in the control group, there were significant differences. The results show that when the extract of Amla emblica is used in combination with the extract of African mango, it has an unexpected synergistic effect on the original effects of lowering blood fat, blood sugar and weight loss of the extract of African mango.

Table 4 Changes of various physiological indicators of subjects in control group 3 and test group 3 before the start of the test and at the end of the test Physiological indicators Control group 3 African mango extract 300 mg Experimental group 3 emblica extract 200 mg + African mango extract 300 mg Statistical Analysis reduce body fat 5.7% 10.1% p < 0.05 reduce cholesterol 10.0% 17.1% p < 0.05 Lower LDL-C 21.7% 27.0% p < 0.05 lower triglycerides 11.3% 16.3% p < 0.05 Improve HDL-C 11.5% 17.0% p < 0.05 lower blood sugar 13.1% 17.4% p < 0.05 Lower waist (cm) 12 18 p < 0.05 Weight loss (kg) 5.4 8.4 p < 0.05 Lower BMI 7.4% 12.0% p < 0.05

It can be seen from Table 5 that the body fat, cholesterol, low density Physiological indicators such as lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and BMI all decreased compared with the corresponding physiological indicators before the start of the test (test day 0), However, the high-density lipoprotein cholesterol (HDL-C) in the blood increased after the 8-week test, and the body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference , body weight, and the degree of decline in physiological indicators such as BMI, as well as the degree of increase in high-density lipoprotein cholesterol (HDL-C), compared with only taking 1500 mg of white kidney bean extract and 500 mg of excipient maltodextrin for a total of 8 Compared with the 4 subjects in the control group, there were significant differences; especially in the degree of blood sugar drop, the significant difference was more obvious (p < 0.001). The results show that when the emblica extract and the white kidney bean extract are used in combination, it has an unexpected synergistic effect on the original effects of the white kidney bean extract on lowering blood fat, blood sugar, and weight loss.

Table 5 Changes of various physiological indicators of subjects in control group 4 and test group 4 before the start of the test and at the end of the test Physiological indicators Control group 4 white kidney bean extract 1500 mg Test group 4 emblica extract 200 mg + white kidney bean extract 1500 mg Statistical Analysis reduce body fat 2.4% 7.3% p < 0.05 reduce cholesterol 1.5% 7.2% p < 0.05 Lower LDL-C 2.5% 8.4% p < 0.05 lower triglycerides 17.2% 23.1% p < 0.05 Improve HDL-C 2.1% 8.5% p < 0.05 lower blood sugar 30.0% 45% p < 0.001 Lower waist (cm) 2.4 5 p < 0.05 Weight loss (kg) 2.3 4.5 p < 0.05 Lower BMI 2.30% 7.0% p < 0.05

It can be seen from Table 6 that the body fat, cholesterol, low-density fat Protein cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and BMI and other physiological indicators were all decreased compared with the corresponding physiological indicators before the start of the test (test day 0), while The high-density lipoprotein cholesterol (HDL-C) in the blood increased after the 8-week test, and the body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, waist circumference, weight, And the degree of decline of physiological indicators such as BMI, and the degree of increase of its high-density lipoprotein cholesterol (HDL-C), compared with the control group that only took 300 mg of camellia seed extract and 1700 mg of excipient maltodextrin for 8 weeks There were significant differences among the 5 subjects. The results show that when the extract of Amla emblica and the extract of camellia seed are used in combination, it has an unexpected synergistic effect on the original effects of reducing blood fat and weight of the extract of camellia seed.

Table 6 Changes of various physiological indicators of subjects in control group 5 and test group 5 before the start of the test and at the end of the test Physiological indicators Control group 5 camellia seed extract 300 mg Experimental group 5 emblica extract 200 mg + camellia seed extract 300 mg Statistical Analysis reduce body fat 1.0% 5.7% p < 0.05 reduce cholesterol 10.0% 18.7% p < 0.05 Lower LDL-C 1.2% 6.7% p < 0.05 lower triglycerides 1.0% 6.2% p < 0.05 Improve HDL-C 2.5% 8.4% p < 0.05 lower blood sugar 1.2% 8.1% p > 0.05 Lower waist (cm) 0 3 p < 0.05 Weight loss (kg) 0.5 3 p < 0.05 Lower BMI 0.5% 4.0% p < 0.05

It can be seen from Table 7 that the subjects in the test group who took 200 mg of Amla emblica extract, 1700 mg of espresso powder and 100 mg of excipient maltodextrin daily for 8 weeks had lower body fat, cholesterol, low-density lipoprotein Physiological indicators such as cholesterol (LDL-C), triglycerides, blood sugar, waist circumference, body weight, and BMI all decreased compared with the corresponding physiological indicators before the start of the test (test day 0), while the other High-density lipoprotein cholesterol (HDL-C) in the blood increased after 8 weeks of testing, and body fat, cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, blood sugar, and BMI, etc. The degree of decrease in physiological indicators, as well as the degree of increase in their high-density lipoprotein cholesterol (HDL-C), compared with the control group 6 subjects who took only 1700 mg of espresso powder and 300 mg of excipient maltodextrin for 8 weeks There are significant differences in comparison. The results show that when the emblica extract is used in combination with espresso powder, it has an unexpected synergistic effect on the original espresso powder's effects of lowering blood fat, blood sugar, and weight loss.

Table 7 Changes of various physiological indicators of subjects in control group 6 and test group 6 before the start of the test and at the end of the test Physiological indicators Control group 6 espresso powder 1700 mg Test group 6 Amla extract 200 mg + espresso powder 1700 mg Statistical Analysis reduce body fat 4.7% 9.5% p < 0.05 reduce cholesterol 13.5% 22.1% p < 0.05 Lower LDL-C 7.5% 13.4% p < 0.05 lower triglycerides 5.0% 10.6% p < 0.05 Improve HDL-C 3.8% 10.4% p < 0.05 lower blood sugar 4.0% 11.3% p < 0.05 Lower waist (cm) 1.3 3.9 p > 0.05 Weight loss (kg) 1.2 3.7 p > 0.05 Lower BMI 2.3% 7.0% p < 0.05

The above detailed description is a specific description of a feasible embodiment of the present invention, but this embodiment is not used to limit the patent scope of the present invention, and any equivalent implementation or change that does not depart from the technical spirit of the present invention shall be included in In the patent scope of this case.

To sum up, the technical features disclosed in this case fully meet the requirements of the statutory invention patent of novelty and advancement. I would like to file an application in accordance with the law. I sincerely ask your bureau to approve this invention patent application to encourage inventions. I am very grateful.

Claims (9)

A composition for reducing metabolic syndrome, comprising an active ingredient composition, the active ingredient composition includes: a emblical extract, the weight percentage is 10%~25%, wherein the emblical extract contains 20% by weight ~30% emblicanin-A (Emblicanin-A), 20%~30% by weight emblicanin-B (Emblicanin-B), 5%~10% by weight Punigluconin, weight percent 10% to 20% of aristolochiin (Pedunculagin), 5% to 15% by weight of rutin (Rutin), and 10% to 30% by weight of ellagitannins (Gallo-ellagitannins); and A second component, the weight percentage is 75%~90%, wherein the second component includes a coffee extract, wherein the coffee extract accounts for 75%~90% by weight of the active ingredient composition, and the The coffee extract contains more than 15% by weight of chlorogenic acid and more than 70 mg/g of caffeine. The composition as claimed in claim 1, wherein the coffee extract is espresso powder. The composition as claimed in claim 1, wherein the second component further comprises a turmeric extract, a garcinia cambogia extract, an African mango extract, a white kidney bean extract, a camellia seed extract or combination. The composition as claimed in claim 3, wherein the coffee extract is espresso powder. The composition according to any one of claims 1 to 4, further comprising a pharmaceutically acceptable carrier. The composition as claimed in item 5, wherein the pharmaceutically acceptable carrier is an excipient. The composition according to claim 6, wherein the excipient is maltodextrin. The composition according to claim 7, wherein the weight ratio of the maltodextrin to the active ingredient composition is 1:19. A use of the composition as described in any one of claims 1 to 4 in the preparation of a pharmaceutical composition for reducing metabolic syndrome.